Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 26

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 26
---
 shares issued and outstanding, pro forma, 34,208,399 
 shares issued and outstanding, pro forma as adjusted                                                                          |     |             |      146,207 |   |     |             |      175,417 |   |     |              |      342,083 |   |
| Additional paid-in capital                                                                                                    |     |             |  411,296,548 |   |     |             |  411,267,338 |   |     |              |  418,256,823 |   |
| Accumulated deficit                                                                                                           |     |             | (410,905,539 | ) |     |             | (410,905,539 | ) |     |              | (410,905,539 | ) |
| Accumulated other comprehensive income                                                                                        |     |             |            — |   |     |             |            — |   |     |              |            — |   |
| Treasury stock                                                                                                                |     |             |      (85,188 | ) |     |             |      (85,188 | ) |     |              |      (85,188 | ) |
| Total stockholders’ equity                                                                                                    |     | $           |      452,028 |   |     | $           |      452,028 |   |     | $            |    7,608,179 |   |
| Total capitalization                                                                                                          |     | $           |      452,028 |   |     | $           |      452,028 |   |     | $            |    7,608,179 |   |

A $0.10 increase
(decrease) in the assumed combined public offering price per share of Common Stock and common warrants of $0.48 would increase
(decrease) the pro forma as adjusted amount of additional paid-in capital, total stockholders’ equity and total capitalization
by approximately $1.6 million ($1.6 million), assuming that the number of shares of Common Stock offered by us, as set
forth on the cover page of this prospectus, remains the same and after deducting estimated Placement Agent fees and estimated offering
expenses payable by us and assuming no exercise of common warrants or sale of pre-funded warrants. An increase (decrease) of 1,000,000
in the number of shares of Common Stock and accompanying common warrants offered by us would increase (decrease) the pro forma as adjusted
amount of additional paid-in capital, total